RA Capital Management, L.P. Increases Stake in UroGen Pharma Ltd
URGN Stock | USD 12.88 0.18 1.42% |
About 52% of UroGen Pharma's investors are presently thinking to get in. The analysis of the overall investor sentiment regarding UroGen Pharma suggests that some traders are interested. UroGen Pharma's investing sentiment overview a quick insight into current market opportunities from investing in UroGen Pharma. Many technical investors use UroGen Pharma stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
UroGen |
Recent Acquisition Overview On September 30, 2024, RA Capital Management, L.P. made a significant addition to its investment portfolio by acquiring 122,841 shar
Read at gurufocus.com
UroGen Pharma Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards UroGen Pharma can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
UroGen Pharma Fundamental Analysis
We analyze UroGen Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of UroGen Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of UroGen Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Sales
Price To Sales Comparative Analysis
UroGen Pharma is currently under evaluation in price to sales category among its peers. Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
UroGen Pharma Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with UroGen Pharma stock to make a market-neutral strategy. Peer analysis of UroGen Pharma could also be used in its relative valuation, which is a method of valuing UroGen Pharma by comparing valuation metrics with similar companies.
Peers
UroGen Pharma Related Equities
PEPG | PepGen | 18.22 | ||||
ERAS | Erasca | 12.94 | ||||
OVID | Ovid Therapeutics | 2.70 | ||||
KRON | Kronos Bio | 2.11 | ||||
CNTB | Connect Biopharma | 1.89 | ||||
CMPX | Compass Therapeutics | 1.84 | ||||
TYRA | Tyra Biosciences | 1.15 | ||||
ELVN | Enliven Therapeutics | 0.21 | ||||
PRTC | PureTech Health | 0.99 | ||||
IKNA | Ikena Oncology | 1.16 | ||||
INBX | Inhibrx | 1.18 | ||||
CELC | Celcuity LLC | 1.33 | ||||
VIGL | Vigil Neuroscience | 2.83 | ||||
EWTX | Edgewise Therapeutics | 4.42 | ||||
XLO | Xilio Development | 4.59 | ||||
SRRK | Scholar Rock | 4.86 | ||||
CCCC | C4 Therapeutics | 5.49 | ||||
ELYM | Eliem Therapeutics | 5.88 | ||||
GBIO | Generation Bio | 6.58 | ||||
TARA | Protara Therapeutics | 15.95 |
Check out UroGen Pharma Hype Analysis, UroGen Pharma Correlation and UroGen Pharma Performance. To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of UroGen Pharma. If investors know UroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about UroGen Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.02) | Revenue Per Share 2.389 | Quarterly Revenue Growth 0.209 | Return On Assets (0.21) | Return On Equity (14.81) |
The market value of UroGen Pharma is measured differently than its book value, which is the value of UroGen that is recorded on the company's balance sheet. Investors also form their own opinion of UroGen Pharma's value that differs from its market value or its book value, called intrinsic value, which is UroGen Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because UroGen Pharma's market value can be influenced by many factors that don't directly affect UroGen Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between UroGen Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if UroGen Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, UroGen Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.